Natera (NASDAQ:NTRA) Price Target Raised to $230.00 at Piper Sandler

Natera (NASDAQ:NTRA) had its price objective boosted by Piper Sandler from $220.00 to $230.00 in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

Several other research firms have also commented on NTRA. Canaccord Genuity Group upped their target price on Natera from $200.00 to $250.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wells Fargo & Company upped their price objective on Natera from $175.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Friday, November 7th. Royal Bank Of Canada set a $268.00 target price on Natera and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. BTIG Research boosted their price target on shares of Natera from $210.00 to $230.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Natera from $210.00 to $240.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Seventeen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $208.58.

Natera Price Performance

Natera stock opened at $206.72 on Tuesday. Natera has a 12 month low of $125.38 and a 12 month high of $210.90. The company has a fifty day moving average price of $179.26 and a two-hundred day moving average price of $164.65. The company has a market cap of $28.53 billion, a PE ratio of -90.27 and a beta of 1.75.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, November 6th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the previous year, the business posted ($0.26) earnings per share. The company’s quarterly revenue was up 34.7% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Natera will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 2,491 shares of the stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $403,666.55. Following the completion of the transaction, the chief financial officer owned 69,189 shares in the company, valued at $11,212,077.45. This represents a 3.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00. Following the sale, the insider owned 117,559 shares in the company, valued at $18,808,264.41. This trade represents a 2.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 224,889 shares of company stock valued at $43,232,062 over the last three months. 5.63% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NTRA. Bank of Jackson Hole Trust acquired a new stake in Natera in the first quarter worth approximately $29,000. TCTC Holdings LLC increased its position in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 124 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in shares of Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after buying an additional 106 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Natera in the second quarter valued at $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in Natera during the second quarter valued at about $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.